TB-500 research and evidence overview

TB-500 research is thymosin beta-4 (Tβ4) research wearing a different label. The parent protein has an extensive animal literature and a genuine clinical development history — phase 2 wound trials, phase 3 ophthalmic trials, phase 2 cardiac trials — while the seven-amino-acid fragment sold as TB-500 has two well-cited preclinical papers to its own name and, as of 2026, one recruiting phase 1/2 human study. There is no completed human efficacy trial of TB-500 for any musculoskeletal or recovery indication.

Before any study can be assigned to TB-500, you have to know what was tested. The label is applied to at least three things: the acetylated LKKTETQ heptapeptide (residues 17–23 of Tβ4), full-length recombinant or synthetic Tβ4, and — per regulator-commissioned analysis — products containing no peptide at all. The University of California–Davis Kenneth L. Maddy Laboratory reported to the Racing Medication and Testing Consortium that many TB-500-labeled products contained no thymosin β4 or peptide derived from it, and that most contained no proteins, peptides, or amino acids whatsoever; one sample did contain N-acetylated LKKTETQ (RMTC Thymosin β4 Bulletin).

The conflation is not confined to vendors. A 2026 rat tendon study describes its test article as "synthetic thymosin beta-4 (TB-500)" (Biçer et al., Jt Dis Relat Surg 2026), so even peer-reviewed sources require reading the methods before assuming which molecule was administered.

Two papers carry most of the weight for the fragment as a distinct entity, and both come out of the Kleinman group:

• Angiogenesis (FASEB J 2003). Using naturally occurring Tβ4, proteolytic fragments, and synthetic peptides, the seven-amino-acid actin-binding motif was found to be essential for angiogenic activity in migration and vessel-sprouting assays (Philp et al.).

• Dermal repair (Wound Repair Regen 2003). In db/db diabetic and aged mice, the synthetic LKKTETQ seven-mer promoted repair in the aged animals "comparable to that observed with the parent molecule" (Philp et al.).

The structural rationale for using this exact segment comes from mutational mapping of Tβ4's actin-binding site, which localized a hexapeptide motif at residues 17–22 with lysine 18 making a key electrostatic contact (Van Troys et al., EMBO J 1996).

The foundational property is actin sequestration: Tβ4 binds G-actin stoichiometrically and inhibits polymerization, established when the actin-sequestering peptide "Fx" proved indistinguishable from thymosin beta-4 (Safer et al., J Biol Chem 1991). From there the animal literature branches:

• Skin: 42% greater reepithelialization at four days and 61% at seven days in rat full-thickness wounds, with 2–3-fold stimulation of keratinocyte migration from as little as 10 pg (Malinda et al., J Invest Dermatol 1999).

• Heart: Tβ4 complexes with PINCH and integrin-linked kinase to activate Akt; after coronary artery ligation in mice it improved myocyte survival and cardiac function (Bock-Marquette et al., Nature 2004).

• Tendon: 60 µg/kg/day for four weeks in repaired rat Achilles tendons significantly increased maximum load to failure and improved Bonar (P=0.016) and Movin (P=0.017) histology scores; combination with BPC-157 added nothing (Biçer et al. 2026).

A synthesis of this biology — actin binding, cell and stem/progenitor cell migration, reduced apoptosis, inflammation and scarring — is compiled in Goldstein et al., Expert Opin Biol Ther 2012.

Two results deserve their numbers. The phase 2 dry-eye study in 72 subjects reported that "neither of the primary endpoints… showed a significant difference between treatment and control groups," while secondary measures did move — controlled-adverse-environment discomfort down 27% (P=0.0244), central corneal staining P=0.0075 (Sosne & Ousler, Clin Ophthalmol 2015). ARISE-3, at n=700, likewise missed its primary outcomes with a statistically significant improvement in ocular grittiness on secondary analysis (P=0.0104, 0.0307, 0.0046) (RegeneRx topline release).

This is the part most TB-500 marketing omits: the parent molecule has been taken to phase 3 twice and has not yet produced a positive pivotal result.

In February 2026 a phase 1/2, randomized, double-blind, placebo-controlled, sequential dose-escalation study of "TB-500 (thymosin beta 4 17-23 fragment)" began recruiting an estimated 80 adults with stable atherosclerotic cardiovascular disease, sponsored by Hudson Biotech at Peking University Shenzhen Hospital, with safety, tolerability, pharmacokinetics, and exploratory cardiovascular biomarkers as objectives and estimated completion in February 2028 (NCT07487363). It is worth being precise about what this does and does not mean: it is the first registered human study of the fragment, it is dose-finding rather than efficacy in injury, and no results exist.

• Check the molecule. Papers using recombinant 43-amino-acid Tβ4 are not evidence about a heptapeptide, and vice versa.

• Check the route. Topical gel, eye drops, intravenous infusion, and intraperitoneal rodent injection are four different exposure profiles.

• Check whether the primary endpoint was met. Both dry-eye programs above are frequently cited as positive because their secondary endpoints moved.

• Check the source of the material. Detection science has had to work around this: equine doping control required establishing endogenous Tβ4 population levels and identifying a non-natural synthesis impurity to prove administration (Delcourt et al., Drug Test Anal 2025).

For context on regulatory status, see the main TB-500 page; for the closest comparison case, BPC-157 vs TB-500.